Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any
revaluation of assets, in the last ten years

Except as disclosed below, our Company and its Subsidiaries have not acquired any business/ undertakings, and have not
undertaken any mergers, amalgamations or any revaluation of assets, in the last ten years.

DMPL

Share purchase agreement dated January 5, 2012 entered into amongst NSPPL (erstwhile Panindia Pharma Distributors
Private Limited), Nitin Pavan Jain, Pavan Kumar Nemichand Jain, Ugambai Jain, Usha Jain, Priyanka Jain (together
“Sellers”) and Deccan Medisales Private Limited (“DMPL”)

Pursuant to the share purchase agreement dated January 5, 2012, NSPPL purchased 10,000 equity shares of DMPL, constituting
100% of the paid-up share capital of DMPL, from the Sellers for an aggregate consideration of 3.10 million

SPDPL

Share purchase agreement dated September 15, 2014 entered into amongst NSPPL (erstwhile Panindia Pharma Distributors
Private Limited), G. Narasimha Reddy (“Seller”), Sidson Pharma Distributors Private Limited (“SPDPL”), read with the
addendum to the share purchase agreement dated March 1, 2016

Pursuant to the share purchase agreement dated September 15, 2014, NSPPL purchased 9,999 equity shares of SPDPL,
constituting 99.99% of the paid-up share capital of SPDPL, from the Seller for a total consideration of 35.1 million.

SBPPL

Share purchase agreement dated September 20, 2014 entered into amongst NSPPL (erstwhile Panindia Pharma Distributors
Private Limited), K N Venkatakrishna, K N Venkatesh (together “Sellers”), Shri Banashankari Pharma Private Limited
(“SBPPL”)

Pursuant to the share purchase agreement dated September 20, 2014, NSPPL purchased 10,000 equity shares of SBPPL,
constituting 100% of the paid-up share capital of SBPPL, from the Sellers for a total consideration of 21.1 million.

Acquisition of Ritemed by Optival
Scheme of Amalgamation between Optival and Ritemed

Optival and Ritemed filed a scheme of amalgamation under Section 232 read with Section 230 of the Companies Act, 2013
before the National Company Law Tribunal, Hyderabad Bench at Hyderabad to merge the business and undertaking of Ritemed,
comprising of retail trading of medicines and general items through various outlets, together with, inter-alia, all assets,
properties, liabilities, duties and obligations whether provided for in the books of accounts or not, intellectual property rights,
trade and service names, confidential information, and employees of Ritemed (“Business Undertaking”) with Optival
(“Scheme of Amalgamation”). The Scheme of Amalgamation was approved by the National Company Law Tribunal,
Hyderabad Bench pursuant to an order dated August 14, 2018. Upon amalgamation, the authorised share capital of Optival was
increased by 2230 million, i.e. the extent of the share capital of Ritemed that was merged with the share capital of Optival.

A certified copy of the order of the Scheme of Amalgamation dated August 14, 2018, was filed with the RoC on October 3,
2018, as required under Section 232(5) of the Companies Act, 2013, and the Scheme of Amalgamation became operative with
effect from April 1, 2016 (“Appointed Date”). Consideration was paid by way of equity shares of Optival issued to the
shareholders of Ritemed, in the ratio of 136 equity shares in Optival of face value 210 at a premium of 226 each, credited as
fully paid-up for every 100 equity shares of Ritemed of 210 each fully paid-up held by the shareholders of Ritemed. The equity
shares issued and allotted by Optival in terms of the Scheme of Arrangement have been ranked pari passu in all respects with
equity shares of Optival existing at the time of allotment.

The Business Undertaking was transferred to and vested in Optival as a going concern as on the Appointed Date. On the
Appointed Date, all liabilities including all secured and unsecured debts, sundry creditors, contingent liabilities, duties and
obligations of every kind utilised for the business activities and operations of Ritemed were transferred to and assumed by
Optival to the extent that they were outstanding. This transfer was on the same terms and conditions as were applicable to
Ritemed and Optival undertook to discharge the obligations arising from all liabilities. All loans and debts raised during the
transition period were be deemed to be taken for the use of Optival and were transferred to Optival.

On the Appointed Date, all legal proceedings pending against Ritemed was continued or executed against Optival, as it would
have been against Ritemed if this Scheme of Amalgamation had not been made. On and from the Appointed Date, Optival

173
